You are here: Industry Insights > Eli Lilly

News List

Eli Lilly on the Hunt for Cancer Deals to Beef Up Pipeline biospace
January 15, 2018
Dave Ricks, CEO and Darren Carroll, Senior Vice President, Business Development, Eli Lilly & Company, Interview at JP Morgan Healthcare Conference in San Francisco
Rimidi, Eli Lilly Enter Partnership for Diabetes Management contractpharma
December 18, 2017
The non-exclusive agreement will aim to make diabetes management easier for both patients and their health care providers
Lilly’s Cyramza fails to improve overall survival in gastric cancer pharmatimes
December 12, 2017
Eli Lilly’s Cyramza has hit its primary goal in a late-stage study showing extended progression-free survival in patients with gastric cancer, but the drug failed to improve overall survival, a secondary endpoint.
Juno Therapeutics signs three license agreements biospectrumasia
December 12, 2017
Through its agreement with Eli Lilly and Company, Juno will acquire a license to the GSI known as LY3039478 which is a product candidate that has been studied in 411 patients and healthy volunteers
Eli Lilly updated status for its 3500 job cuts plan fiercepharma
November 10, 2017
Eli Lilly has a status update for its massive round of job cuts aimed at saving $500 million per year: Around 2,300 employees have taken voluntary early retirements, and Lilly is "on track to achieve" the 3,500 cuts it laid out in September.
Pfizer leads Big Pharma's emerging markets growth as GlaxoSmithKline, Eli Lilly lag fiercepharma
September 21, 2017
Big Pharma’s businesses in emerging markets grew 6.1% sequentially in the second quarter, the fastest in more than two years, according to a recent tally by Bernstein analysts, but some grew much faster than others.
Eli Lilly to cut 3500 jobs globally; shutdown R&D sites biospectrumasia
September 15, 2017
The reductions will result in yearly savings of about $500 million, beginning in 2018
Eli Lilly to invest more in new medicines and drive growth biospectrumasia
September 11, 2017
With the streamlining efforts announced, the company expects annualized savings of approximately $500 million that will begin to be realized in 2018
Topas and Lilly sign deal to focus on immune tolerance pharmaceutical-technology
August 24, 2017
German biotechnology company Topas Therapeutics has signed a multi-year agreement with Eli Lilly and Company to jointly work on antigen-specific tolerance induction, with an initial focus on external antigens thought to induce inflammation and / or autoim
Lilly pens deal for Evotec spinout’s immune tolerance drugs fiercebiotech
August 23, 2017
Eli Lilly's headquartersTopas spun out of Evotec last year, picking up €14 million ($16 million) from its parent company and other investors along the way.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page